Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
GLP-1 Drugs and AF Risk in CKD
A matched CKD cohort linked GLP-1 receptor agonist use with less atrial fibrillation, but the retrospective design cannot prove prevention.
GLP-1 Drugs Around Hand Surgery
A 2026 review finds limited, mostly retrospective evidence on GLP-1 drugs around hand surgery. Results do not settle aspiration risk or medication timing.
GLP-1 Drugs and Sexual Function Evidence
A 2026 dermatology letter flags sexual function as a missing GLP-1 safety outcome. With no abstract, related studies provide context rather than its findings.
Semaglutide and CKD Valve Calcification
A multi-method preclinical study linked SIRT1 loss to CKD-related valve calcification and found a semaglutide signal in cells and mice.
Tirzepatide Cardiac Mouse Study
A mouse and cell study linked tirzepatide with less cardiac microvascular injury, while leaving PRKN dependence and human relevance unresolved.
Tirzepatide and Treatment Simplification
A 12-month Japanese study linked tirzepatide with more diabetes treatment simplification than conventional GLP-1 medicines, but it was retrospective.
Tirzepatide and Sleep Apnea Endotypes
A single SURMOUNT-OSA participant had major changes in sleep apnea and airway physiology after tirzepatide, but one case cannot establish mechanism.
Semaglutide in Pakistan: 30-Week Data
A 30-week Pakistan study linked biosynthetic semaglutide with lower HbA1c and weight, but its single-arm design limits causal conclusions.
GLP-1R-Gs Molecular Dynamics Study
A 2026 simulation compared GLP-1, semaglutide, and tirzepatide at GLP-1R-Gs, finding structural hypotheses rather than clinical outcomes.
Semaglutide and Asthma-COPD Overlap
A network meta-analysis linked injectable semaglutide with fewer asthma-COPD overlap events, but the respiratory outcome was rarely prespecified.
PCSK5 Heart Repair Mouse Study
A patient-linked and mouse study tied endothelial PCSK5 to angiogenesis, cardiac repair, and one preclinical semaglutide response.
Who Fits Semaglutide Heart Criteria?
A registry study mapped cardiology patients to SELECT and SOUL criteria. It estimates potential semaglutide eligibility, not who should be treated.